Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/95586
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hsieh, R. | - |
dc.contributor.author | Chan, A. | - |
dc.contributor.author | Kim, H. | - |
dc.contributor.author | Yu, S. | - |
dc.contributor.author | Kim, J. | - |
dc.contributor.author | Lee, M. | - |
dc.contributor.author | Dalén, J. | - |
dc.contributor.author | Jung, H. | - |
dc.contributor.author | Liu, Y. | - |
dc.contributor.author | Burke, T. | - |
dc.contributor.author | Keefe, D. | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | Supportive Care in Cancer, 2014; 23(1):263-272 | - |
dc.identifier.issn | 0941-4355 | - |
dc.identifier.issn | 1433-7339 | - |
dc.identifier.uri | http://hdl.handle.net/2440/95586 | - |
dc.description.abstract | PURPOSE: This paper describes the incidence of chemotherapy-induced nausea and vomiting (CINV) after highly or moderately emetogenic chemotherapy (HEC or MEC) for cancer in six Asia Pacific countries. METHODS: Sequential adult patients naïve to chemotherapy and scheduled to receive at least two cycles of single-day HEC or MEC were enrolled in this prospective observational study. Patients completed the Multinational Association of Supportive Care in Cancer (MASCC) Antiemesis Tool on post-chemotherapy days 2 and 6 to record acute-phase (first 24 h) and delayed-phase (days 2-5) CINV. RESULTS: There were 648 evaluable patients (318 HEC, 330 MEC) from Australia (n = 74), China (153), India (88), Singapore (57), South Korea (151), and Taiwan (125). Mean (SD) patient age was 56 (12) and 58% of patients were women; the most common primary cancers were breast (27%), lung (22%), and colon (20%). Overall in cycle 1, complete response (no emesis or rescue antiemetics) was recorded by 69% (95% confidence interval (CI), 66-73) of all evaluable patients, with country percentages ranging from 55 to 78% (p < 0.001). After HEC, no emesis was recorded by 75% and no nausea by 38% of patients. After MEC, 80% had no emesis and 50% no nausea. Acute-phase CINV was better controlled than delayed-phase CINV, and the control of nausea was the lowest of any CINV measure in all phases. In a CINV perception survey, physicians tended to overestimate emesis rate and underestimate nausea rate. CONCLUSIONS: CINV remains a substantial problem, and country-specific information about CINV can be useful in developing strategies to improve outcomes for patients undergoing chemotherapy. | - |
dc.description.statementofresponsibility | Ruey Kuen Hsieh, Alexandre Chan, Hoon-Kyo Kim, Shiying Yu, Jong Gwang Kim, Myung-Ah Lee, Johan Dalén, Hun Jung, Yan Ping Liu, Thomas A. Burke, Dorothy M. K. Keefe | - |
dc.language.iso | en | - |
dc.publisher | Springer-Verlag | - |
dc.rights | © Springer-Verlag Berlin Heidelberg 2014 | - |
dc.source.uri | http://dx.doi.org/10.1007/s00520-014-2373-2 | - |
dc.subject | Chemotherapy-induced nausea and vomiting; Incidence; Observational; Prescribing patterns | - |
dc.title | Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1007/s00520-014-2373-2 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Keefe, D. [0000-0001-9377-431X] | - |
Appears in Collections: | Aurora harvest 7 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.